NuCana

NCNA NASDAQ
11.94
+0.29
+2.49%
休市 16:00 06/14 EDT
开盘
12.79
昨收
11.65
最高
12.79
最低
11.73
成交量
4,095
成交均量(3M)
4.56万
52周最高
30.10
52周最低
10.37
换手率
0.01%
市值
3.80亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供NuCana NCNA股票价格,NuCana股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
展开 >

最近浏览

名称
价格
涨跌幅